Vendor, Doylestown, PA
Baruch S. Blumberg Institute
UEI NAYCKSJB7F68, CAGE 47W56
2 awards and $10,746,974 obligated between April 18, 2024 and July 24, 2026, 100% under full and open competition, against 6.5 offers on average where reported.
Sells to
Awarding agencies by dollars.
| National Institutes of Health | $10,746,974 |
| Defense Contract Management Agency | $0 |
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $10,746,974 |
| Professional, Scientific, and Technical ServicesNAICS 541712 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 2 |
| Definitive Contract | 2 |
Hear when Baruch S. Blumberg Institute wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Baruch S. Blumberg Institute holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $10,746,974
- Soonest
- November 30, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) to National Institutes of Health, by dollars.
| Leidos Biomedical Research Inc.Frederick, MD | $2,186,453,292 |
| Westat, Inc.Rockville, MD | $762,955,645 |
| Technical Resources International, Inc.Bethesda, MD | $196,391,189 |
| Duke UniversityDurham, NC | $158,758,507 |
| MriglobalKansas City, MO | $117,921,746 |
| The Johns Hopkins UniversityBaltimore, MD | $100,932,043 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93023C00003Definitive Contract, April 18, 2024, Full and Open Competition, 10 offers | National Institutes of Health NiaidNational Institutes of Health | To Develop an Orally Available Small Molecule Antiviral Drug, with Treatment of Yellow Fever Virus Infection as the Primary Indication.NAICS 541715, PSC AN12 | $10,746,974 |
| W911SR09C0018Definitive Contract, April 25, 2024, Full and Open Competition, 3 offers | DCMA Mid-AtlanticDefense Contract Management Agency | Funding/AdminNAICS 541712, PSC AD92 | $0 |
- Places of performance
- Pennsylvania
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied ResearchAD92
- Transactions
- 10 across 2 awards